Theravance to Split

Source: PharmaManufacturing.com

Apr 29, 2013

Reuters

Biopharmaceutical company Theravance Inc said it plans to split its business into two publicly traded companies.
One of the companies, Royalty Management Co, will focus on developing drugs under Theravance's collaboration with British drug giant GlaxoSmithKline Plc, Theravance said on Thursday.

The other, Theravance Biopharma, will focus on development of small-molecule compounds in rare disease areas.

Theravance reported a first-quarter net loss of $37.4 million, or 39 cents per share, compared with a profit of $84.6 million, or $1.01 per share, a year earlier. Read the full story.
Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments